Past, present and future of therapies in pediatric sarcomas

Future Oncology

Volumn 6, Issue 4, 2010, Pages 605-618

  Hingorani, Pooja ^a   Kolb, Edward A ^b  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Bisphosphonate; IGF; MTOR; Oncolytic virus; Pediatric sarcoma; Targeted therapy

Indexed keywords

4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; ADW 742; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BMS 536924; DENOSUMAB; EVEROLIMUS; FIGITUMUMAB; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MURAMYL TRIPEPTIDE; MURAMYL TRIPEPTIDE PHOSPHATIDYLETHANOLAMINE; NVP AEW 541; ONCOLYTIC VIRUS; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; SENECA VALLEY VIRUS OO1; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C DERIVATIVE; SOMATOMEDIN C RECEPTOR; SORAFENIB; TEMSIROLIMUS; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

ADRENAL CORTEX CARCINOMA; ANGIOSARCOMA; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONTINUOUS INFUSION; CYTOPENIA; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG DOSE ESCALATION; DRUG FEVER; DRUG HYPERSENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPENDYMOMA; EPIGENETICS; EWING SARCOMA; GENE TARGETING; GLIOMA; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; LEUKEMIA; LIGAND BINDING; LUNG CANCER; LUNG METASTASIS; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MEDULLOBLASTOMA; MELANOMA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; RETINOBLASTOMA; REVIEW; RHABDOMYOMA; SARCOMA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; SYNOVIAL SARCOMA; VIRAL GENE DELIVERY SYSTEM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; SARCOMA; SIGNAL TRANSDUCTION;

EID: 77950625037     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.19     Document Type: Review

References (124)

1. Marina N, Gebhardt M, Teot L, Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9(4), 422-441 (2004). (Pubitemid 39014554)
2. Esiashvili N, Goodman M, Marcus RB Jr: Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J. Pediatr. Hematol. Oncol. 30(6), 425-430 (2008).
3. Kim SY, Toretsky JA, Scher D, Helman LJ: The role of IGF-1R in pediatric malignancies. Oncologist 14(1), 83-91 (2009).
4. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL: Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res. 55(1), 129-134 (1995).
5. Clemmons DR, Busby WH, Arai T et al.: Role of insulin-like growth factor binding proteins in the control of IGF actions. Prog. Growth Factor Res. 6(2-4), 357-366 (1995).
6. Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y, LeRoith D: Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 121(1), 19-26 (1998). (Pubitemid 28561545)
7. Minniti CP, Tsokos M, Newton WA Jr, Helman LJ: Specific expression of insulin-like growth factor-II in rhabdomyosarcoma tumor cells. Am. J. Clin. Pathol. 101(2), 198-203 (1994). (Pubitemid 24061448)
8. Wang W, Kumar P, Epstein J, Helman L, Moore JV, Kumar S: Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res. 58(19), 4426-4433 (1998). (Pubitemid 28450047)
9. Zhan S, Shapiro DN, Helman LJ: Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 11(12), 2503-2507 (1995). (Pubitemid 26023817)
10. Yun K: A new marker for rhabdomyosarcoma. Insulin-like growth factor II. Lab. Invest. 67(5), 653-664 (1992).
11. Cao L, Yu Y, Darko I et al.: Addiction to elevated insulin-like growth factor I receptor and initial modulation of the Akt pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 68(19), 8039-8048 (2008).
12. Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR: Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr. Dev. Pathol. 12(2), 127-135 (2009).
13. Ayalon D, Glaser T, Werner H: Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm. IGF Res. 11(5), 289-297 (2001). (Pubitemid 34257726)
14. Kolb EA, Gorlick R, Houghton PJ et al.: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(6), 1190-1197 (2008). (Pubitemid 351555543)
15. Arvand A, Denny CT: Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20(40), 5747-5754 (2001).
16. Toretsky JA, Steinberg SM, Thakar M et al.: Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 92(11), 2941-2947 (2001). (Pubitemid 33091932)
17. Yee D, Favoni RE, Lebovic GS et al.: Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J. Clin. Invest. 86(6), 1806-1814 (1990).
18. Rikhof B, De Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT: The insulin-like growth factor system and sarcomas. J. Pathol. 217(4), 469-482 (2009).
19. Burrow S, Andrulis IL, Pollak M, Bell RS: Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J. Surg. Oncol. 69(1), 21-27 (1998). (Pubitemid 28452269)
20. Avnet S, Sciacca L, Salerno M et al.: Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 69(6), 2443-2452 (2009).
21. Savage SA, Woodson K, Walk E et al.: Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev. 16(8), 1667-1674 (2007). (Pubitemid 47294836)
22. Pollak M, Sem AW, Richard M, Tetenes E, Bell R: Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J. Natl Cancer Inst. 84(12), 966-971 (1992).
23. De Bruijn DR, Allander SV, van Dijk AH et al.: The synovial-sarcoma- associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation. Cancer Res. 66(19), 9474-9482 (2006).
24. Friedrichs N, Kuchler J, Endl E et al.: Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J. Pathol. 216(4), 428-439 (2008).
25. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O: Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res. 59(15), 3588-3591 (1999). (Pubitemid 29381857)
26. Werner H, Idelman G, Rubinstein M, Pattee P, Nagalla SR, Roberts CT Jr: A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Cancer Lett. 247(1), 84-90 (2007). (Pubitemid 44959411)
27. Scotlandi K, Manara MC, Nicoletti G et al.: Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65(9), 3868-3876 (2005). (Pubitemid 40616368)
28. Martins AS, Mackintosh C, Martin DH et al.: Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin. Cancer Res. 12(11 Pt 1), 3532-3540 (2006).
29. Martins AS, Ordonez JL, Garcia-Sanchez A et al.: A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 68(15), 6260-6270 (2008).
30. Huang F, Greer A, Hurlburt W et al.: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69(1), 161-170 (2009).
31. Wood ER, Shewchuk L, Hassel A et al.: Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor. Biochem. Pharmacol. 78(12), 1438-1447 (2009).
32. Pappo A, Patel S, Crowley J et al.: A SARC global collaborative PHASE II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas. Presented at: CTOS 15th Annual Meeting. Miami Beach, FL, USA, 5-7 November (2009) (Abstract).
33. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ: The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 69(19), 7662-7671 (2009).
34. Atzori F TT, Ionta MT, Massidda B: Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol. 4(4) 255-266 (2009).
35. Ikeda H, Shiojima I, Ozasa Y et al.: Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced cardiac hypertrophy. J. Mol. Cell. Cardiol. 47(5), 664-675 (2009).
36. Devin JK, Young PP: The effects of growth hormone and insulin-like growth factor-1 on the aging cardiovascular system and its progenitor cells. Curr. Opin. Invest. Drugs 9(9), 983-992 (2008).
37. Kaplan RC, Strickler HD, Rohan TE, Muzumdar R, Brown DL: Insulin-like growth factors and coronary heart disease. Cardiol. Rev. 13(1), 35-39 (2005). (Pubitemid 40204695)
38. Dobrucki LW, Tsutsumi Y, Kalinowski L et al.: Analysis of angiogenesis induced by local IGF-1 expression after myocardial infarction using microSPECT-CT imaging. J. Mol. Cell Cardiol. DOI: doi:10.1016/j.yjmcc.2009.10. 008 (2009) (Epub ahead of print).
39. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296(5573), 1655-1657 (2002).
40. Manning BD, Cantley LC: United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 31(Pt 3), 573-578 (2003).
41. Petricoin EF 3rd, Espina V, Araujo RP et al.: Phosphoprotein pathway mapping: Akt/ mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 67(7), 3431-3440 (2007). (Pubitemid 46724884)
42. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ: Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 54(4), 903-907 (1994). (Pubitemid 24085438)
43. Houghton PJ, Morton CL, Kolb EA et al.: Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr. Blood Cancer 50(4), 799-805 (2008). (Pubitemid 351354788)
44. Wan X, Mendoza A, Khanna C, Helman LJ: Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65(6), 2406-2411 (2005). (Pubitemid 40490152)
45. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA: Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin. Cancer Res. 15(2), 589-596 (2009).
46. Hartford CM, Desai AA, Janisch L et al.: A Phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res. 15(4), 1428-1434 (2009).
47. Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F: Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin. Invest. Drugs 17(12), 1947-1954 (2008).
48. O'Donnell A, Faivre S, Burris HA 3rd et al.: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J. Clin. Oncol. 26(10), 1588-1595 (2008).
49. Spunt SL, Grupp S, Vik T: Phase I, safety, pharmacokinetic, exploratory biomarker study of intravenous temsirolimus in children with advanced solid tumors. Am. Soc. Pediatr. Hematol. Oncol. (2007) (Abstract).
50. Mita MM, Mita AC, Chu QS et al.: Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26(3), 361-367 (2008).
51. Bertrand FE, Steelman LS, Chappell WH et al.: Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 20(7), 1254-1260 (2006).
52. Kurmasheva RT, Huang S, Houghton PJ: Predicted mechanisms of resistance to mTOR inhibitors. Br. J. Cancer 95(8), 955-960 (2006).
53. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A: Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin. Cancer Res. 15(10), 3451-3461 (2009).
54. Reszka AA, Rodan GA: Bisphosphonate mechanism of action. Curr. Rheumatol. Rep. 5(1), 65-74 (2003).
55. Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol. Pharmacol. 71(1), 333-343 (2007). (Pubitemid 46021003)
56. Ferretti G, Fabi A, Carlini P et al.: Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69(1), 35-43 (2005). (Pubitemid 41207056)
57. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T: Zoledronic acid - a multiplicity of anti-cancer action. Curr. Med. Chem. 14(20), 2126-2135 (2007). (Pubitemid 47578153)
58. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F: Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104(11), 2522-2529 (2005). (Pubitemid 41691577)
59. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F: The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12(5), 459-465 (2001). (Pubitemid 32643090)
60. Green JR, Clezardin P: Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am. J. Clin. Oncol. 25(6 Suppl. 1), S3-S9 (2002). (Pubitemid 35453651)
61. Benassi MS, Chiechi A, Ponticelli F et al.: Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett. 250(2), 194-205 (2007). (Pubitemid 46529443)
62. Horie N, Murata H, Kimura S et al.: Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br. J. Cancer 96(2), 255-261 (2007). (Pubitemid 46160630)
63. Zhou Z, Guan H, Duan X, Kleinerman ES: Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104(8), 1713-1720 (2005). (Pubitemid 41437436)
64. Cameron D: Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast 12(Suppl. 2), S22-S29 (2003). (Pubitemid 40023560)
65. Ibrahim A, Scher N, Williams G et al.: Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin. Cancer Res. 9(7), 2394-2399 (2003).
66. Berenson JR, Rosen LS, Howell A et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91(7), 1191-1200 (2001).
67. Rosen LS: Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin. Oncol. 29(6 Suppl. 21), 28-32 (2002).
68. Garcia Saenz JA, Lopez Tarruella S, Garcia Paredes B, Rodriguez Lajusticia L, Villalobos L, Diaz Rubio E: Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med. Oral Patol. Oral Cir. Bucal. 12(5), E351-E356 (2007).
69. Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP: Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr. Cancer Drug Targets 6(2), 123-133 (2006).
70. Ullrich SE, Fidler IJ: Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens. J. Leukoc. Biol. 52(5), 489-494 (1992).
71. Dzierzbicka K, Gozdowska M, Kolodziejczyk AM: [L-MTP-PE - a potential antineoplastic agent]. Postepy. Hig. Med. Dosw. 51(2), 227-236 (1997).
72. Anderson P: Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol. 2(3), 333-343 (2006).
73. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS, Jaffe N: Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am. J. Clin. Oncol. 18(2), 93-99 (1995).
74. Meyers PA, Schwartz CL, Krailo MD et al.: Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J. Clin. Oncol. 26(4), 633-638 (2008).
75. Chou AJ, Kleinerman ES, Krailo MD et al.: Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 115(22), 5339-5348 (2009).
76. Sugiura S, Goshima F, Takakuwa H, Sata T, Nakashima T, Nishiyama Y: Treatment of solid sarcomas in immunocompetent mice with novel, oncolytic herpes simplex viruses. Otolaryngol. Head Neck Surg. 130(4), 470-478 (2004).
77. Bharatan NS, Currier MA, Cripe TP: Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J. Pediatr. Hematol. Oncol. 24(6), 447-453 (2002).
78. Currier MA, Adams LC, Mahller YY, Cripe TP: Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther. 12(4), 407-416 (2005).
79. Graat HC, Van Beusechem VW, Schagen FH et al.: Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol. Cancer 7, 9 (2008).
80. Ketola A, Hinkkanen A, Yongabi F et al.: Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res. 68(20), 8342-8350 (2008).
81. Reddy PS, Burroughs KD, Hales LM et al.: Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J. Natl Cancer Inst. 99(21), 1623-1633 (2007).
82. Thirukkumaran C, Morris DG: Oncolytic viral therapy using reovirus. Methods Mol. Biol. 542, 607-634 (2009).
83. Wadhwa L, Hurwitz MY, Chevez-Barrios P, Hurwitz RL: Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Cancer Res. 67(22), 10653-10656 (2007).
84. Gidwani P, Zhang E, Guha C, Liu L, Kolb EA: Systemic administration of reolysin inhibits growth of human sarcoma xenografts alone and in combination with cisplatin and radiation. Presented at: American Association for Cancer Research (AACR) 2008 Annual Meeting. San Diego, CA, USA, 12-16 April (2008) (Abstract).
85. Vidal L, Pandha HS, Yap TA et al.: A Phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin. Cancer Res. 14(21), 7127-7137 (2008).
86. Mita A, Sankhala K, Sarantopoulos J et al.: A Phase II study of intravenous reolysin (wild type reovorus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. Presented at: CTOS 15th Annual Meeting. Miami Beach, FL, USA, 5-7 November (2009) (Abstract).
87. Kim M, Chung YH, Johnston RN: Reovirus and tumor oncolysis. J. Microbiol. 45(3), 187-192 (2007).
88. Berghuis D, De Hooge AS, Santos SJ et al.: Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J. Pathol. 218(2), 222-231 (2009).
89. Brinkrolf P, Landmeier S, Altvater B et al.: A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease. Int. J. Cancer 125(4), 879-886 (2009).
90. Ackermann B, Troger A, Glouchkova L, Korholz D, Gobel U, Dilloo D: Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis. Klin. Padiatr. 216(3), 176-182 (2004).
91. Guo W, Guo Y, Tang S, Qu H, Zhao H: Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity. Clin. Orthop. Relat. Res. 466(9), 2176-2183 (2008).
92. Rodeberg DA, Erskine C, Celis E: In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. J. Pediatr. Surg. 42(8), 1396-1402 (2007).
93. Merchant MS, Melchionda F, Sinha M, Khanna C, Helman L, Mackall CL: Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol. Immunother. 56(7), 1037-1046 (2007).
94. De Angulo G, Hernandez M, Morales- Arias J et al.: Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J. Pediatr. Hematol. Oncol. 29(1), 48-52 (2007).
95. Geiger JD, Hutchinson RJ, Hohenkirk LF et al.: Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61(23), 8513-8519 (2001).
96. Mackall CL, Rhee EH, Read EJ et al.: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin. Cancer Res. 14(15), 4850-4858 (2008).
97. Rosenberg SA, Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21(2), 233-240 (2009).
98. Erba E, Bergamaschi D, Bassano L et al.: Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer 37(1), 97-105 (2001).
99. Li WW, Takahashi N, Jhanwar S et al.: Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin. Cancer Res. 7(9), 2908-2911 (2001).
100. Blay JY, Le Cesne A, Verweij J et al.: A Phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer 40(9), 1327-1331 (2004).
101. Lau L, Supko JG, Blaney S et al.: A Phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin. Cancer Res. 11(2 Pt 1), 672-677 (2005).
102. Lipton A, Jun S: RANKL inhibition in the treatment of bone metastases. Curr. Opin. Support Palliat. Care 2(3), 197-203 (2008).
103. Body JJ, Facon T, Coleman RE et al.: A study of the biological receptor activator of nuclear factor-kB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin. Cancer Res. 12(4), 1221-1228 (2006).
104. Bartsch R, Steger GG: Role of denosumab in breast cancer. Expert Opin. Biol. Ther. 9(9), 1225-1233 (2009).
105. Vij R, Horvath N, Spencer A et al.: An open-label, Phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am. J. Hematol. 84(10), 650-656 (2009).
106. Lipton A, Steger GG, Figueroa J et al.: Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin. Cancer Res. 14(20), 6690-6696 (2008).
107. Fizazi K, Lipton A, Mariette X et al.: Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27(10), 1564-1571 (2009).
108. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep. 9(2), 115-119 (2007).
109. Hurwitz HI, Dowlati A, Saini S et al.: Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15(12), 4220-4227 (2009).
110. Sonpavde G, Hutson TE, Sternberg CN: Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin. Invest. Drugs 17(2), 253-261 (2008).
111. Sleijfer S, Ray-Coquard I, Papai Z et al.: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC study 62043). J. Clin. Oncol. 27(19), 3126-3132 (2009).
112. Podar K, Tonon G, Sattler M et al.: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc. Natl Acad. Sci. USA 103(51), 19478-19483 (2006).
113. Sloan B, Scheinfeld NS: Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr. Opin. Invest. Drugs 9(12), 1324-1335 (2008).
114. Liu L, Cao Y, Chen C et al.: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006).
115. Peng CL, Guo W, Ji T et al.: Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol. Ther. 8(18), 1729-1736 (2009).
116. Pignochino Y, Grignani G, Cavalloni G et al.: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol. Cancer 8, 118 (2009).
117. Maki RG, D'Adamo DR, Keohan ML et al.: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J. Clin. Oncol. 27(19), 3133-3140 (2009).
118. Pan LN, Lu J, Huang B: HDAC inhibitors: a potential new category of anti-tumor agents. Cell. Mol. Immunol. 4(5), 337-343 (2007).
119. Sakimura R, Tanaka K, Nakatani F et al.: Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors. Int. J. Cancer 116(5), 784-792 (2005).
120. Ito T, Ouchida M, Morimoto Y et al.: Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett. 224(2), 311-319 (2005).
121. Hurtubise A, Bernstein ML, Momparler RL: Preclinical evaluation of the antineoplastic action of 5-aza-2́-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. Cancer Cell Int. 8, 16 (2008).
122. Yamamoto S, Tanaka K, Sakimura R et al.: Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines. Anticancer Res. 28(3A), 1585-1591 (2008).
123. Sakimura R, Tanaka K, Yamamoto S et al.: The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells. Clin. Cancer Res. 13(1), 275-282 (2007).
124. Keshelava N, Houghton PJ, Morton CL et al.: Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr. Blood Cancer 53(3), 505-508 (2009).